P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells.

Abstract

Atractylenolide I (Atr-I) was found to sensitize a variety of human cancer cells in previous studies. Purinergic P2X7R plays important role in different cancers. However, whether Atr-I could generate antitumor activity in human cervical cancer cells and P2X7R get involved in this effect remain unclear. In this study, Hela (HPV 18 +) and SiHa (HPV 16 +) cells were treated with different doses of Atr-I. The results indicated that agonist and antagonist of P2X7 receptors, BzATP and JNJ-47965567 (JNJ), could suppress the proliferation of Hela and SiHa cells. Atr-I demonstrated a considerable antitumor effect in both human cervical cancer cells in vitro. Atr-I combined with P2X7R agonist, BzATP, restored Atr-I-induced growth inhibition in Hela cells but not in SiHa cells. However, the combinatorial treatment of P2X7R antagonist JNJ and Atr-I has an additive effect on cell growth inhibition in SiHa cells rather than in Hela cells. It implied that P2X7R would get involved in the anti-human cervical cancer cells effect of Atr-I.

• Authors: Yue Han, Can Bai, Xi-Meng He, Qing-Ling Ren
• Journal: Purinergic signalling (Purinergic Signal) Vol. 19 Issue 1 Pg. 145-153 (03 2023) ISSN: 1573-9546 [Electronic] Netherlands
• PMID: 35235139 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• atractylenolide I
• Purinergic P2X Receptor Antagonists
• Receptors, Purinergic P2X7
• Antineoplastic Agents

Topics

• Female
• Humans
• Cell Proliferation
• HeLa Cells
• Purinergic P2X Receptor Antagonists (pharmacology)
• Receptors, Purinergic P2X7
• Uterine Cervical Neoplasms
• Antineoplastic Agents (therapeutic use)